- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06414265
Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation (CASSINI-EU)
Reduction or Elimination of Mitral Regurgitation With the SATURN Trans-Septal TMVR System in Patients With Severe Symptomatic Mitral Regurgitation - CASSINI-EU Trial
The goal of this clinical trial is to evaluate feasibility, safety, and performance of the SATURN TS TMVR System for the treatment of moderate-to-severe or severe, symptomatic mitral regurgitation through a transcatheter approach. The main questions it aims to answer are:
- is the use of the device feasible?
- is it safe (defined as freedom from device-related major adverse events at 30 days)?
- does it perform (defined as reduction of MR Grade to ≤ 1+ at 30 days)?
Participants will need to do the following as part of the clinical trial:
- complete 6-Minute Walking Test
- complete Quality of Life Questionnaires
- undergo blood evaluations
- CT scan
- 12 lead ECG
- Transesophageal Echocardiography
- Transthoracic Echocardiogram
- the study procedure (valve implantation, right heart catheterization, left arterial pressure, fluoroscopy/ angiogram)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The SATURN Trans-Septal Transcatheter Mitral Valve Replacement System (SATURN TS System) is intended for use in adult patients suffering from heart failure symptoms (NYHA class II or greater) with moderate to severe or severe mitral regurgitation (MR ≥3+) who are deemed to be at high risk for open-heart mitral valve surgery by a multidisciplinary Heart Team including at least a cardiac surgeon and a cardiologist, experienced in the care of patients with mitral valve disease.
CASSINI-EU is a single-arm, prospective, multicenter pilot trial. The purpose of the study is to evaluate feasibility, safety, and performance of the SATURN TS TMVR System for the treatment of moderate-to-severe or severe, symptomatic mitral regurgitation through a transcatheter approach.
Primary objectives are to evaluate the feasibility, safety and performance of the SATURN TS TMVR System at 30 days. Secondary objectives and additional outcomes are long term safety and performance of the SATURN TS TMVR System.
Up to 30 patients will be treated at up to 6 qualified investigational sites in Europe.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: VP, Clinical Affairs InnovHeart
- Phone Number: +49 69 24003626
- Email: a.roach@innovheart.com
Study Contact Backup
- Name: Maxis Operations
- Email: maxisoperations@maxismedical.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 65 years or older.
- Symptomatic moderate to severe or severe functional mitral regurgitation (≥ Grade 3+).
- NYHA functional Class ≥ II. If Class IV, patient must be ambulatory.
- Ability to tolerate oral anticoagulation.
- Ability to qualify for bailout surgery (which may include open heart surgery).
- High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team.
- Willing and able to complete study-related assessments and questionnaires.
Exclusion Criteria:
General Exclusion Criteria
- Degenerative (i.e. intrinsic valve lesions) mitral regurgitation.
- Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement.
- Life expectancy <1 year due to noncardiac conditions.
- Endocarditis in the 3 months prior to procedure date.
- Current admission with acute heart failure exacerbation.
- Dependency on inotropic agents or mechanical circulatory support.
- Untreated clinically significant CAD.
- Active systemic infection.
- Modified Rankin Scale ≥4 disability.
- Chronic renal failure defined as eGFR <30 mL/min/m2 or on renal replacement therapy.
- Severe pulmonary arterial hypertension (PAH), defined as PASP > 60mmHg.
- Platelets < 90,000.
- COPD 2 on home oxygen therapy deemed too high risk for intubation.
- Refuses blood transfusions.
- Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states).
- Severe connective tissue disease under chronic immunosuppressive or cortisone therapy.
- Participating in other investigational studies likely to confound the results or affect the study.
- Unable or does not sign the study informed consent form.
Patients classified as "vulnerable patients" 3 .
Cardiovascular Exclusion Criteria
- Myocardial infarction during prior 30 days.
- Stroke or TIA during prior 90 days.
- Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed).
- Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment.
- Prior surgical mechanical valve AVR.
- Prior TAVI.
- Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure.
- CRT or ICD implanted in previous 30 days.
- Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure <90mmHg, Inotropic dependent or requiring IABP/mechanical circulatory support.
- CABG or PCI within previous 30 days.
- Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee.
- Prior or planned heart transplantation (UNOS status 1).
Physical evidence of right-sided congestive heart failure:
- Patients with ascites.
- Patients with anasarca (generalized edema / hydropsy).
Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy.
Procedural Exclusion Criteria
- Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy).
- Documented hypersensitivity to nickel or titanium.
Contraindications to TEE imaging
Cardiac Imaging Exclusion Criteria
- Left ventricular EF ≤ 30% by echocardiogram.
- Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass.
- Extensive mitral flail leaflets
- Evidence of new or untreated intracardiac thrombus, mass, or vegetation.
- Severe right ventricular dysfunction.
- Severe tricuspid regurgitation.
- Hemodynamically significant inter-atrial shunt (ASD).
- Severe aortic regurgitation or aortic stenosis.
- Anatomic ineligibility for SATURN TS Bioprosthetic System or SATURN TS procedure as determined by the Screening Committee.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
SATURN Trans-septal Transcatheter mitral valve replacement (TMVR) System
|
The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Endpoint - Freedom from Device Related Major Adverse Events
Time Frame: 30 days post-procedure
|
Freedom from device-related major adverse events
|
30 days post-procedure
|
Technical Procedural Success Endpoint
Time Frame: Procedure
|
Technical success defined as alive patient at exit from procedure room with all the following:
|
Procedure
|
Efficacy Endpoint - Reduction of Mitral Regurgitation Grade to ≤ 1+
Time Frame: 30 days post-procedure
|
Reduction of MR Grade to ≤ 1+
|
30 days post-procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paolo Denti, MD, San Raffaele Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TP-0181
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on Transcatheter mitral valve replacement
-
Caisson Interventional LLCActive, not recruitingMitral Regurgitation | Valve Disease, Heart | Valve Heart Disease | Mitral Valve Disease | Mitral Valve Failure | Mitral DiseaseUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Edwards LifesciencesActive, not recruitingMitral Valve Regurgitation (Degenerative or Functional)United States, Canada
-
HighLife SASMedPass International; ICON plcActive, not recruitingMitral Valve Insufficiency | Mitral Valve RegurgitationFrance, Germany
-
Mayra GuerreroHenry Ford HospitalCompleted
-
HighLife SASRecruitingMitral RegurgitationUnited States
-
HighLife SASICON plcRecruitingMitral RegurgitationBelgium, France, Germany, Australia, United Kingdom, Poland
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecruitingHeart Failure | Mitral Regurgitation | Mitral Stenosis | Mitral Stenosis With Insufficiency | Bioprosthesis FailureChina
-
P+F Products + Features GmbHMeditrial USA Inc.Not yet recruitingMitral Regurgitation | Mitral Valve DiseaseBrazil, Argentina, Chile
-
Neovasc Inc.Active, not recruitingMitral Valve RegurgitationUnited States, Canada, Belgium